Oxidation of low-density lipoprotein and atherosclerosis in chronic renal failure.
The major cause of death in patients with end-stage renal failure receiving renal replacement therapy is cardiovascular disease. Oxidation of low-density lipoprotein (LDL) is recognized as a key early stage in the development of atherosclerosis, leading to uptake of LDL by the macrophage scavenger receptor and hence to foam cell formation. However, several studies have suggested that the susceptibility of LDL to oxidation is not increased in chronic renal failure. We propose a number of mechanisms which may lead to increased lipoprotein oxidation in vivo, and hence contribute to increased atherosclerosis in renal failure.
Hasselwander
O
O
Department of Clinical Biochemistry, Queen's University of Belfast, Northern Ireland, UK.
Young
I S
IS
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001161:Arteriosclerosis / Q000209:etiology / Q000378:metabolism*; D005609:Free Radicals; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D010084:Oxidation-Reduction
D000975:Antioxidants; D005609:Free Radicals; D008077:Lipoproteins, LDL